Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous Non-Small Cell Lung Cancer: The Phase 3 SKYSCRAPER-06 Randomized Clinical Trial [0.03%]
Mark A Socinski,Rolf Stahel,Dae Ho Lee et al.
Mark A Socinski et al.
Importance: Programmed cell death 1 ligand 1/programmed cell death protein 1 inhibitors, with or without chemotherapy, are standard first-line treatment for patients with advanced non-small cell lung cancer (NSCLC); howev...
Chao Cao,Kathryn H Schmitz,Edward L Giovannucci et al.
Chao Cao et al.
Local Salvage Therapy Alone for Local Recurrence of Prostate Cancer After Radiotherapy: A Systematic Review and Meta-Analysis [0.03%]
Marcin Miszczyk,Federico Mastroleo,Anna Kujawska et al.
Marcin Miszczyk et al.
Importance: Standard-of-care management of radiorecurrent prostate cancer (PCa) involves systemic therapy; however, some patients seek to avoid the adverse events (AEs) that are associated with androgen-deprivation therap...
Asad M Lak,Shruthi Kondaboina,Satoshi Yamaguchi
Asad M Lak
Yang Yang
Yang Yang
Long-Term Outcomes of Patients With BRCA+ or PALB2+ Pancreatic Cancer Treated With Maintenance Rucaparib: A Secondary Analysis of a Nonrandomized Clinical Trial [0.03%]
Kim A Reiss,Mingyi Xia,Mwangala Akamandisa et al.
Kim A Reiss et al.
Paulo S Pinheiro,Tabassum Z Insaf,Amber N Balda et al.
Paulo S Pinheiro et al.
Importance: Adult T-cell leukemia/lymphoma (ATLL) is a rare but highly aggressive malignant disease caused by lifelong infection with human T-cell leukemia virus type 1 (HTLV-1), typically acquired through mother-to-child...
Rethinking Treatment Intent Beyond the Curative/Palliative Binary in Modern Oncology [0.03%]
现代肿瘤学中重新考虑治愈/姑息治疗二元论之外的治疗目的
Hanneke W M van Laarhoven,Inge Henselmans,Peter S N van Rossum
Hanneke W M van Laarhoven
Reassessing Treatment Outcomes Following Immune-Related Adverse Events-Reply [0.03%]
对免疫相关不良事件后治疗结果的再评估-回信
Joseph M Unger,Dawn L Hershman
Joseph M Unger
Koichiro Yuji,Wakako Yuji
Koichiro Yuji